AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11134438
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron + EPO group (2 mg/kg/day of intravenous iron sucrose, r‐HuEPO, and oral iron)
Trial: 8381146
Drug: Vinblastine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 5 minutes after BBL injection
Trial: 8381146
Drug: Control lesions
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lesions (BBL, saline, or no treatment)
Trial: 19093004
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations (PfAMA1 with Alhydrogel, Montanide ISA720, AS02)
Trial: 16966690
Drug: Belagenpumatucel-L (1.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belagenpumatucel-L (1.25, 2.5, or 5.0 x 10(7) cells/injection) administered monthly or every other month for a maximum of 16 injections
Trial: 14582545
Drug: Cannulated screws
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cannulated screws combined with calcium‐phosphate cement for augmentation
Trial: 10699943
Drug: T+GLA (Gamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+GLA (Gamma linolenic acid with tamoxifen 20 mg od)
Trial: 10699943
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg od alone
Trial: 8411294
Drug: Standard auricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard auricular acupuncture treatment
Trial: 8411294
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (geographically close points)
Trial: 31895658
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 fatty acids (1 g/d)
Trial: 15784492
Drug: Intravenous supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous supplementary nutrition (1000 kcal/day for 3 days, followed by oral supplementary nutrition (400 kcal/day for 7 days))
Trial: 11897546
Drug: 20% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% human albumin 50 ml
Trial: 7916403
Drug: Recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-2 (1 MU) with hepatitis B vaccine (20 micrograms)
Trial: 7916403
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with hepatitis B vaccine (20 micrograms)
Trial: 31033364
Drug: Naproxen 220-750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 220-750 mg/day
Trial: 26722699
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health training for care-staff
Trial: 26722699
Drug: Scaled up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaled up oral health training for all staff
Trial: 7890075
Drug: Synchronized administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synchronized administration of hCG at the onset of the endogenous LH rise (J group)
Trial: 7890075
Drug: Non-synchronized administration
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-synchronized administration of hCG (non-J group)
Trial: 1854108
Drug: Aminophylline (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (loading dose followed by routine infusion, n = 65)
Trial: 1854108
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal volume as loading dose and infusion, n = 68)
Trial: 6661511
Drug: Medroxalol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxalol solution (100 mg)
Trial: 6661511
Drug: Medroxalol tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxalol tablet formulation (100 mg)
Trial: 6661511
Drug: Medroxalol intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxalol intravenous (100 mg)
Trial: 15037490
Drug: Light to
RxNorm normalized name: MINERAL OIL,LIGHT TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light to moderate alcohol consumption (monthly, weekly, daily)
Trial: 15037490
Drug: Light to
RxNorm normalized name: MINERAL OIL,LIGHT TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light to moderate alcohol consumption (monthly, weekly, daily) among men with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg
Trial: 11709512
Drug: Balsalazide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 3.0 g twice daily
Trial: 11709512
Drug: Balsalazide 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 1.5 g twice daily
Trial: 11709512
Drug: Mesalazine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 0.5 g three times daily
Trial: 8561442
Drug: verapamil LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil LI 120 mg 3 times a day
Trial: 8561442
Drug: verapamil LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil LP 120 mg twice a day
Trial: 2122015
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (BSHGH) 0.1 mg/kg/day for 7 days
Trial: 2122015
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (BSHGH)
Trial: 21834489
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg + atorvastatin 10 mg
Trial: 21834489
Drug: atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 20 mg + placebo
Trial: 15729016
Drug: Cefaclor 50
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 50 mg/kg/day for 5 days
Trial: 15729016
Drug: Cefaclor 40
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor 40 mg/kg/day for 10 days
Trial: 9210991
Drug: Pre-treatment depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment depression
Trial: 9210991
Drug: Interpersonal problems
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal problems at pre-treatment
Trial: 8353046
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant interleukin-2 (rIL-2) at dose levels of 0.18, 0.6, 1.8, or 6 x 10(6) IU m-2 24 h-1; one patient treated with 3 x 10(6) IU m-2 24 h-1
Trial: 2297142
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with oral immunotherapy (Artemisia pollen extract) over a 50-day course, cumulative dose of 396,652 PNU
Trial: 268377
Drug: 1 APF
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 APF tablet containing 1 mg fluoride
Trial: 268377
Drug: 2 APF
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 APF tablets (3 hours apart) each school day
Trial: 268377
Drug: 1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet
Trial: 31554360
Drug: HDR brachytherapy
RxNorm normalized name: OCTOCRYLENE 5 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL / HOMOSALATE 2 g in 100 mL TOPICAL CREAM [Mineralium Hdra Source Moisturizing Protector SPF 25]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDR brachytherapy with concurrent chemotherapy (Paclitaxel and Carboplatin)
Trial: 24288948
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (1 g/day for 3 months)
Trial: 16409457
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin (AT)
Trial: 8493292
Drug: Hormonal levels
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal levels (thyroid stimulating hormone, free triiodothyronine, prolactin, cortisol)
Trial: 2942050
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin 10 mg
Trial: 2942050
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin 20 mg
Trial: 2942050
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection of saline
Trial: 27261936
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (3 mg/kg body weight)
Trial: 25029008
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (DHA) 2 g/day for 28 days
Trial: 25029008
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) 2 g/day for 28 days
Trial: 22659999
Drug: Vitamin B‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐12 (500 µg/day) for 12 weeks
Trial: 16171665
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg/kg IV followed by continuous infusion of 0.5 mg/kg per hour until the end of surgery (group I)
Trial: 12854475
Drug: 2 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg.kg-1 propofol (group P2)
Trial: 12854475
Drug: 1 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg-1 propofol (group P1)
Trial: 12854475
Drug: Intralipid 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 0.2 ml.kg-1 (group C)
Trial: 9884384
Drug: Isoproterenol (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (before NG‐monomethyl‐L‐arginine)
Trial: 9884384
Drug: Isoproterenol (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (after NG‐monomethyl‐L‐arginine)
Trial: 1651071
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 13‐cis‐retinoic acid
Trial: 1651071
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of all‐trans‐retinoic acid
Trial: 1651071
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of arotinoid methyl sulphone
Trial: 1651071
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of arotinoid ethyl sulphone
Trial: 30716769
Drug: Placebo creams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo creams
Trial: 6352603
Drug: Azlocillin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azlocillin (group I) at mean dosage of 252 mg/kg/day for a mean duration of 13.2 days
Trial: 6352603
Drug: Carbenicillin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin (group II) at mean dosage of 505 mg/kg/day for a median duration of 12.6 days
Trial: 26575606
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment initiation in overt diabetes
Trial: 12377958
Drug: EPI alone
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI alone (60 mg/m(2) on days 1 and 2 every 21 days)
Trial: 12377958
Drug: EPI and
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI and CDDP (30 mg/m(2) on days 1 and 2 every 21 days)
Trial: 12377958
Drug: EPI and
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI and LND (450 mg orally daily, given continuously)
Trial: 7863045
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (AB) 50-100 mg/day
Trial: 821075
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered thyrotropin-releasing hormone (TRH) at a dosage of 200 to 300 mg daily
Trial: 31610635
Drug: Delivery mode,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery mode, feeding method and antibiotic exposure
Trial: 28599630
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (1.8 g daily, containing 1.08 g of EPA and 0.72 g of DHA)
Trial: 21709652
Drug: i.v. midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. midazolam 1 mg
Trial: 21709652
Drug: i.v. midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. midazolam 3 mg
Trial: 14711553
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, p.o. b.i.d.)
Trial: 11355560
Drug: Iron‐folate supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron‐folate supplements (36 mg iron and 5 mg folate daily)
Trial: 11355560
Drug: Control (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (neither albendazole nor iron‐folate supplements)
Trial: 9146577
Drug: Vaginal mucosal
RxNorm normalized name: Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal mucosal immunization (vaccine treated)
Trial: 29342272
Drug: Qualitative interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative interviews regarding decision-making about food and drink, dietary supplements, medications, alcohol, and recreational drugs.
Trial: 28126600
Drug: Romifidine 60
RxNorm normalized name: romifidine
DrugBank: Romifidine (DB11543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine 60 μg/kg IV (R60)
Trial: 28126600
Drug: Romifidine 80
RxNorm normalized name: romifidine
DrugBank: Romifidine (DB11543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine 80 μg/kg IV (R80)
Trial: 28126600
Drug: Romifidine 100
RxNorm normalized name: romifidine
DrugBank: Romifidine (DB11543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine 100 μg/kg IV (R100)
Trial: 28126600
Drug: Romifidine 40
RxNorm normalized name: romifidine
DrugBank: Romifidine (DB11543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine 40 μg/kg IV (R40)
Trial: 28126600
Drug: Acepromazine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acepromazine 0.1 mg/kg IV (ACE)
Trial: 28126600
Drug: Saline (0.9%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9%, 5 mL IV)
Trial: 23176568
Drug: Nanoparticle paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanoparticle paclitaxel 300 mg/m² (NP300)
Trial: 23176568
Drug: Nanoparticle paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanoparticle paclitaxel 220 mg/m² (NP220)
Trial: 23176568
Drug: Cremophor paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cremophor paclitaxel 175 mg/m² (CP175)
Trial: 22000624
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of oxygenation, blood cultures, rapid initiation of antibiotic therapy <4 hours, appropriate selection of antibiotic therapy
Trial: 18434883
Drug: Piperacillin/tazobactam 12/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 12/1.5 g/day after a loading dose of 4/0.5 g
Trial: 18434883
Drug: Piperacillin/tazobactam 16/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 16/2 g/day after a loading dose of 4/0.5 g
Trial: 16256232
Drug: CHART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHART treatment
Trial: 1318678
Drug: Daptomycin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 2.0 mg/kg
Trial: 1318678
Drug: Daptomycin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 3.0 mg/kg
Trial: 1318678
Drug: Daptomycin 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 4.0 mg/kg
Trial: 1318678
Drug: Daptomycin 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 6.0 mg/kg
Trial: 1318678
Drug: Daptomycin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 1.0 mg/kg (14C-labeled)
Trial: 1318678
Drug: Daptomycin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 0.5 to 6.0 mg/kg
Trial: 1318678
Drug: Daptomycin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (all doses)
Trial: 1318678
Drug: Daptomycin (predicted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (predicted effective doses)
Trial: 30741801
Drug: Oxytocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (30 units in 500 mL of intravenous fluid)
Trial: 30741801
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL of intravenous fluid alone)
Trial: 27724859
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.15 μg·kg−1·min−1) followed by immobility
Trial: 17294149
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic drugs combined with psychotherapy
Trial: 16118079
Drug: 6 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses of anthracycline-based chemotherapy (CT group)
Trial: 12270028
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg taken 4 hours before expected time of sex for 6 months
Trial: 10052020
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg vitamin C capsule daily during weeks 4-5
Trial: 10052020
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily during weeks 1-3
Trial: 2174464
Drug: Infusion regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion regimen of etoposide (VP‐16) and cisplatin (CDDP)
Trial: 2174464
Drug: Infusion regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion regimen
Trial: 6999637
Drug: Danazol treatment
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol treatment for 6 months
Trial: 29522648
Drug: Darifenacin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 10 mg or 20 mg
Trial: 24222312
Drug: High-dose-rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) with long-term androgen deprivation therapy (ADT)
Trial: 2178566
Drug: Acetyl-salicylic acid
RxNorm normalized name: acetyl salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-salicylic acid (ASA) 1000 mg/day
Trial: 89499
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immunoglobulin (HBIg) 0.5 ml/kg within 48 hours after birth and 0.16 ml/kg every month for 6 months
Trial: 30079635
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion (1 mg bolus over 30 minutes followed by 2 μg/kg/h continuous infusion)
Trial: 23507223
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (2 capsules and 4 cups water per day)
Trial: 19470058
Drug: Strip patch
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Strip patch test (SPT)
Trial: 19470058
Drug: Conventional patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional patch test (PT)
Trial: 17052563
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 1 mg/kg
Trial: 17052563
Drug: i.m. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. ketamine 4 mg/kg
Trial: 8522684
Drug: Intracoronary isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary isosorbide dinitrate (2 mg)
Trial: 6303624
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thallium score, appearance of Q waves, and ejection fraction
Trial: 30215545
Drug: Leniolisib (CDZ173),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leniolisib (CDZ173), single oral dose of 400 mg
Trial: 26823180
Drug: Intensive journal
RxNorm normalized name: Journavx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive journal club treatment arm
Trial: 22166903
Drug: Salbutamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (15 μg/kg ideal bodyweight per h) for up to 7 days